Esophageal Cancer Clinical Trial
Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients
Summary
The purpose of this study is to demonstrate that orally administered itraconazole, a commonly used antifungal medication, can inhibit Hedgehog pathway signaling in patients with esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).
Eligibility Criteria
Inclusion Criteria:
• Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer
Exclusion Criteria:
Patients unwilling or unable to provide informed consent
Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count <100,000/mm3, INR>1.5)
Esophageal varices
Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe participation in the study
QTc>450 ms
LFT's>3xULN
Pregnancy
Allergy to itraconazole
History of symptomatic congestive heart failure
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Dallas Texas, 75216, United States
How clear is this clinincal trial information?